Company to Share Clinical Development Plans and Corporate Strategy with Potential Partners
Cambridge, Mass., USA, May 31, 2018 / B3C newswire / -- Thrombolytic Science, LLC (TSI), a clinical stage vascular health company developing biotechnology products to treat thrombotic diseases such as myocardial infarction (MI, or heart attack) and stroke, today announced that it will meet with potential partners at the 25th BIO International Conference from June 4th to June 7th in Boston, Mass.
TSI recently completed a Phase I clinical trial of its treatment regimen, a next-generation clot-dissolving therapy that mimics nature’s safe and efficient fibrinolytic system in the treatment of clot-induced diseases. A first-in-human, randomized, double-blind, placebo-controlled study demonstrated the overall safety and tolerability of its treatment regimen in healthy adults. TSI is now preparing to enter human proof-of-concept trials in patients experiencing ischemic stroke and MI.
The only treatment currently available for ischemic stroke is tissue plasminogen activator (tPA), which requires to be administrated within a 0-to-4.5-hour time window, and which carries a risk of brain hemorrhage. The main treatment for heart attacks is primary percutaneous coronary intervention (PCI, or balloon angioplasty), an invasive procedure that may cause smaller clots to break off and occlude smaller vessels downstream of the initial blockage, thereby increasing risk of future events.
“We are excited to participate in the 2018 BIO International Conference and share our vision and plans regarding the potential for changing treatment standards in blood clot-related diseases,” said Alexis Wallace, M.Sc.Eng., MBA, President and Chief Executive Officer of TSI. “We encourage BIO guests to use the One-on-One Partnering platform to schedule meetings with TSI representatives.”
About Thrombolytic Science
Thrombolytic Science is a privately-held vascular health and biotechnology company aiming to transform traditional approaches to treating thrombotic diseases using a proven approach that mimics human biological processes. TSI’s proprietary treatment regimen is a next-generation sequential combination therapy, using low doses of two biological activators of clot degradation – tPA and HisproUK – which together effectively and safely dissolve blood clots. HisproUK is a proprietary, rationally designed, single-site mutant of native prourokinase (proUK).
TSI will soon investigate the efficacy and safety of its sequential combination treatment regimen in two Phase II trials, and plans to develop treatments for ischemic stroke, heart attacks and other clot-induced diseases. TSI’s technology is based upon pioneering earlier work on proUK by the Vascular Research Laboratory.